|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0019704,
umls-concept:C0030946,
umls-concept:C0080194,
umls-concept:C0086418,
umls-concept:C0178719,
umls-concept:C0185117,
umls-concept:C0205419,
umls-concept:C0598312,
umls-concept:C1548328,
umls-concept:C1553412,
umls-concept:C2911684
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1996-12-30
|
|
pubmed:abstractText |
The enzymatic activity of the human immunodeficiency type 1 (HIV-1) protease (PR) is crucial to render HIV-1 virions mature and infectious. Hence, genetic intervention strategies based on trans-dominant (td) variants of the HIV-1 PR might be an alternative to current pharmacological and gene therapy regimens for AIDS. CD4-positive human CEM-SS T-cell lines were generated which constitutively expressed HIV-1 td PR variants. HIV-1 infection experiments demonstrated severely reduced HIV-1 replication in these td PR CEM-SS cell lines compared with control T cells expressing wild-type PR. Furthermore, replication of an HIV-1 isolate bearing a PR inhibitor-resistant PR was blocked, showing that genetic intervention strategies based on td PRs can be effective against HIV-1 isolates containing PR inhibitor-resistant mutants.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-1402661,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-1409715,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-1688646,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-1712325,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-1803993,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-1883539,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-1988010,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-2214018,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-2405486,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-2447506,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-2548279,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-2657099,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-2676192,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-2788277,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-2988790,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-3040055,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-3052288,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-3170585,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-3281026,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-3290901,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-3306411,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-3321060,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-3357211,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-6206563,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-7477168,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-7479728,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-7535864,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-7578399,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-7700387,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-7815519,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-7815532,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-8155773,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-8170964,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-8388497,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8892897-8551047
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0022-538X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
70
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7765-72
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:8892897-CD4-Positive T-Lymphocytes,
pubmed-meshheading:8892897-Cell Line,
pubmed-meshheading:8892897-Drug Resistance, Microbial,
pubmed-meshheading:8892897-Gene Expression,
pubmed-meshheading:8892897-Genetic Variation,
pubmed-meshheading:8892897-HIV Protease,
pubmed-meshheading:8892897-HIV-1,
pubmed-meshheading:8892897-Humans,
pubmed-meshheading:8892897-Methylurea Compounds,
pubmed-meshheading:8892897-Plasmids,
pubmed-meshheading:8892897-Protease Inhibitors,
pubmed-meshheading:8892897-Pyridines,
pubmed-meshheading:8892897-Virus Replication
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Intracellular expression of human immunodeficiency virus type 1 (HIV-1) protease variants inhibits replication of wild-type and protease inhibitor-resistant HIV-1 strains in human T-cell lines.
|
|
pubmed:affiliation |
Progenesys Program at Systemix, Palo Alto, California 94304, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
